OncoMatch/Clinical Trials/NCT06081673

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

Is NCT06081673 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Penpulimab and cisplatin for head and neck squamous cell carcinoma.

Phase 2RecruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT06081673Data as of May 2026

Treatment: Penpulimab · cisplatin · albumin-paclitaxel — This study aims to observe and explore the efficacy and safety of Penpulimab combined with chemotherapy for neoadjuvant and adjuvant therapy in patients with resectable head and neck squamous cell carcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Required: Stage III, IVA

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: anti-PD-1/PD-L1/CTLA-4 therapy

Patients who have previously used PD-1/PD-L1/CTLA-4 antibody therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify